324 related articles for article (PubMed ID: 33402049)
1.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
2. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
Yousif FA; Alzain AA; Alraih AM; Ibraheem W
PLoS One; 2023; 18(9):e0291256. PubMed ID: 37682937
[TBL] [Abstract][Full Text] [Related]
5. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
6.
Alamri A; Rauf A; Khalil AA; Alghamdi A; Alafnan A; Alshammari A; Alshammari F; Malik JA; Anwar S
Biomed Res Int; 2021; 2021():9734279. PubMed ID: 34957309
[TBL] [Abstract][Full Text] [Related]
7. Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis.
Moldogazieva NT; Ostroverkhova DS; Kuzmich NN; Kadochnikov VV; Terentiev AA; Porozov YB
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019136
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of binding and antagonism/downregulation of brilanestrant molecule in estrogen receptor-α via quantum mechanics/molecular mechanics, molecular dynamics and binding free energy calculations.
Chinnasamy K; Saravanan M; Poomani K
J Biomol Struct Dyn; 2020 Jan; 38(1):219-235. PubMed ID: 31038398
[TBL] [Abstract][Full Text] [Related]
9. Identification of small molecule inhibitors of RAD52 for breast cancer therapy: in silico approach.
Kumar M; Dubey R; Kumar Shukla P; Dayal D; Kumar Chaubey K; Tsai LW; Kumar S
J Biomol Struct Dyn; 2024 Jun; 42(9):4605-4618. PubMed ID: 37288783
[TBL] [Abstract][Full Text] [Related]
10. Aspirin as a potential drug repurposing candidate targeting estrogen receptor alpha in breast cancer: a molecular dynamics and in-vitro study.
Kaur D; Choudhury C; Yadav R; Kumari L; Bhatia A
J Biomol Struct Dyn; 2024 Jan; ():1-12. PubMed ID: 38279948
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel small molecule inhibitors for endoplasmic reticulum oxidoreductase 1α (ERO1α) enzyme: structure-based molecular docking and molecular dynamic simulation studies.
Albassam H; Mehta CH; Nayak UY
J Biomol Struct Dyn; 2022; 40(23):13218-13232. PubMed ID: 34606425
[TBL] [Abstract][Full Text] [Related]
12. Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERα) by various parameters and molecular modelling approach.
Puranik NV; Srivastava P; Bhatt G; John Mary DJS; Limaye AM; Sivaraman J
Sci Rep; 2019 May; 9(1):7450. PubMed ID: 31092862
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between the ligand- and DNA-binding domains of estrogen receptor.
Huang W; Greene GL; Ravikumar KM; Yang S
Proteins; 2013 Nov; 81(11):1900-9. PubMed ID: 23737157
[TBL] [Abstract][Full Text] [Related]
14. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
15. Designer interface peptide grafts target estrogen receptor alpha dimerization.
Chakraborty S; Asare BK; Biswas PK; Rajnarayanan RV
Biochem Biophys Res Commun; 2016 Sep; 478(1):116-122. PubMed ID: 27462021
[TBL] [Abstract][Full Text] [Related]
16. Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation.
Schultz DJ; Wickramasinghe NS; Ivanova MM; Isaacs SM; Dougherty SM; Imbert-Fernandez Y; Cunningham AR; Chen C; Klinge CM
Mol Cancer Ther; 2010 Mar; 9(3):594-605. PubMed ID: 20197399
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer therapy.
Qin W; Xie M; Qin X; Fang Q; Yin F; Li Z
Bioorg Med Chem Lett; 2018 Sep; 28(17):2827-2836. PubMed ID: 30025900
[TBL] [Abstract][Full Text] [Related]
18. Computational identification of new TKI as potential noncovalent reversible EGFR
Abdelmalek D; Smaoui F; Frikha F; Ben Marzoug R; Msalbi D; Souissi A; Aifa MS
J Biomol Struct Dyn; 2024 Jun; 42(9):4870-4887. PubMed ID: 37349947
[TBL] [Abstract][Full Text] [Related]
19. Structure-based virtual screening, molecular simulation and free energy calculations of traditional Chinese medicine, ZINC database revealed potent inhibitors of estrogen-receptor α (ERα).
Shahab M; Zulfat M; Zheng G
J Biomol Struct Dyn; 2023 Oct; ():1-14. PubMed ID: 37904521
[TBL] [Abstract][Full Text] [Related]
20. Dynamacophore model for breast cancer estrogen receptor alpha as an effective lead generation screening technique.
Shanmugarajan D; Biju A; Sibi D; Sibi R; Shaji M; David C
J Biomol Struct Dyn; 2023; 41(22):13029-13040. PubMed ID: 37154819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
